Deep Track Capital LP Takes Position in Galapagos NV (NASDAQ:GLPG)

Deep Track Capital LP acquired a new position in shares of Galapagos NV (NASDAQ:GLPG - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 780,778 shares of the biotechnology company's stock, valued at approximately $21,471,000. Deep Track Capital LP owned about 1.18% of Galapagos at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Gilead Sciences Inc. bought a new stake in shares of Galapagos during the fourth quarter valued at approximately $461,727,000. Finepoint Capital LP lifted its holdings in Galapagos by 21.0% in the fourth quarter. Finepoint Capital LP now owns 674,762 shares of the biotechnology company's stock valued at $18,556,000 after buying an additional 117,000 shares during the period. Renaissance Technologies LLC lifted its holdings in Galapagos by 1.5% in the fourth quarter. Renaissance Technologies LLC now owns 296,100 shares of the biotechnology company's stock valued at $8,143,000 after buying an additional 4,421 shares during the period. Norges Bank acquired a new position in Galapagos in the fourth quarter valued at approximately $3,300,000. Finally, Crossmark Global Holdings Inc. lifted its holdings in Galapagos by 31.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 49,163 shares of the biotechnology company's stock valued at $1,352,000 after buying an additional 11,777 shares during the period. 32.46% of the stock is owned by institutional investors.

Galapagos Stock Performance

Shares of GLPG traded up $0.05 during mid-day trading on Monday, reaching $25.37. The company's stock had a trading volume of 220,033 shares, compared to its average volume of 219,014. Galapagos NV has a 1-year low of $22.36 and a 1-year high of $31.23. The business has a 50-day simple moving average of $25.41 and a two-hundred day simple moving average of $25.92.

Galapagos (NASDAQ:GLPG - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) EPS for the quarter, missing the consensus estimate of ($0.23) by ($2.24). The company had revenue of $97.33 million for the quarter, compared to analyst estimates of $72.22 million. On average, equities research analysts expect that Galapagos NV will post -1.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

GLPG has been the topic of several analyst reports. StockNews.com lowered shares of Galapagos from a "hold" rating to a "sell" rating in a report on Friday, April 25th. Barclays reiterated an "underweight" rating on shares of Galapagos in a report on Thursday, January 23rd. Finally, Morgan Stanley lowered shares of Galapagos from an "equal weight" rating to an "underweight" rating and cut their target price for the stock from $31.00 to $22.00 in a report on Friday, February 14th. Five investment analysts have rated the stock with a sell rating and four have issued a hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Reduce" and an average price target of $25.33.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.